

Beneficial Effect of N-acetylcysteine on Antineutrophil Cytoplasmic Antibody-associated Vasculitis

To the Editor:

We read with interest the recent contribution by Drs. Fernández-Fernández and Sesma¹. They introduced 2 significant studies: the IFIGENIA trial (Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual study)² and the study by Guilpain, *et al*³ showing that antimyeloperoxidase (MPO) antibodies generated a reactive oxygen species that was highly harmful to endothelial cells, and that N-acetylcysteine (NAC) significantly reduced the activation of MPO and improved the survival of endothelial cells through the augmentation of glutathione biosynthesis. However, we would like to add another mechanism of NAC that will be useful as adjuvant therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies (ANCA).

According to a study by Spapen, *et al*⁴, NAC had no significant effects on plasma tumor necrosis factor, interleukin 6 (IL-6), or IL-10 levels, but greatly decreased IL-8 during early human septic shock. Hsieh, *et al*⁵ reported that the polymorphonuclear neutrophil (PMN)-stimulating activity of ANCA was demonstrated by enhancing IL-8 production that was more prominent by MPO-ANCA. The production of IL-8 by PMN was significantly increased by anti-MPO ($p < 0.01$) and antiproteinase-3 ($p < 0.05$) after 24 h of incubation⁵. IL-8, the specific chemoattractant of PMN, enhances release of lysosomal enzymes and generation of reactive oxygen metabolites from PMN⁶. However, the PMN stimulation by ANCA was not through protein kinase, H₂O₂, or superoxide anion radicals because their inhibitors exerted no effect on ANCA-mediated activation⁵.

Therefore, it is possible that NAC may be useful and helpful as adjuvant therapy for patients with ANCA-associated vasculitis through inhibition of IL-8 rather than reactive oxygen species. It would also be interesting to measure the level of IL-8 before and after the treatment of NAC in patients with ANCA-associated vasculitis. However, further studies are necessary to elucidate the real pathways of ANCA-mediated PMN activation by IL-8 and the clinical effect of NAC in the disease process.

SE JIN PARK, MD; KI SOO PAI, MD, Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, Suwon; JI HONG KIM, MD; JAE IL SHIN, MD, The Institute of Kidney Disease, Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea. Address correspondence to Dr. J. Shin, 250 Sungsan-ro, Seodaemun-gu, CPO Box 8044, Department of Pediatrics, Yonsei University College of Medicine, Seoul 120-752, Korea. E-mail: shinji@yuhs.ac

REFERENCES

1. Fernández-Fernández FJ, Sesma P. Acetylcysteine as adjuvant therapy for vasculitis associated with antineutrophil cytoplasmic antibody. *J Rheumatol* 2011;38:785.
2. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al for the IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med* 2005;353:2229-42.
3. Guilpain P, Servettaz A, Batteux F, Guillevin L, Mouthon L. Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies. *Autoimmun Rev* 2008;7:421-5.
4. Spapen H, Zhang H, Demanet C, Vleminckx W, Vincent JL, Huyghens L. Does N-acetyl-L-cysteine influence cytokine response during early human septic shock? *Chest* 1998;113:1616-24.
5. Hsieh SC, Yu HS, Cheng SH, Li KJ, Lu MC, Wu CH, et al. Anti-myeloperoxidase antibodies enhance phagocytosis, IL-8 production, and glucose uptake of polymorphonuclear neutrophils rather than anti-proteinase 3 antibodies leading to activation-induced cell death of the neutrophils. *Clin Rheumatol* 2007;26:216-24.
6. Willems J, Joniau M, Cinque S, van Damme J. Human granulocyte chemotactic peptide (IL-8) as a specific neutrophil degranulator: Comparison with other monokines. *Immunology* 1989;67:540-2.

J Rheumatol 2012;39:1; doi:10.3899/jrheum.111025